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Abstract 
Short Communication on t(9;15)(p13;q24) 
PAX5/PML, with data on clinics, and the genes 
implicated. 
Identity 
Note 
The translocation is noted with various breakpoints 
on chromosome 15, ranging from q22 to q25 (this is 
reminiscent of the t(15;17) PML/RARA). 
Clinics and pathology 
Disease 
B-cell acute lymphoblastic leukemia (B-ALL) 
Epidemiology 
Two cases to date, a 9-month old girl and a 1.5-year 
old boy, both with a CD10+ ALL (Nebral et al., 
2007; Nebral et al., 2009). 
Prognosis 
A patient remains in complete remission 84 months 
from diagnosis, while the other one had a testicular 
relapse 2 years after diagnosis and died. 
Cytogenetics 
Cytogenetics morphological 
The translocation was the sole abnormality. 
 
 
Genes involved and 
proteins 
PAX5 
Location 
9p13.2 
Protein 
391 amino acids; from N-term to C-term, PAX5 
contains: a paired domain (aa: 16-142); an 
octapeptide (aa: 179-186); a partial homeodomain 
(aa: 228-254); a transactivation domain (aa: 304-
359); and an inhibitory domain (aa: 359-391). 
Lineage-specific transcription factor; recognizes the 
concensus recognition sequence 
GNCCANTGAAGCGTGAC, where N is any 
nucleotide. Involved in B-cell differentiation. Entry 
of common lymphoid progenitors into the B cell 
lineage depends on E2A, EBF1, and PAX5; 
activates B-cell specific genes and repress genes 
involved in other lineage commitments. Activates 
the surface cell receptor CD19 and repress FLT3. 
Pax5 physically interacts with the RAG1/RAG2 
complex, and removes the inhibitory signal of the 
lysine-9-methylated histone H3, and induces V-to-
DJ rearrangements. Genes repressed by PAX5 
expression in early B cells are restored in their 
function in mature B cells and plasma cells, and 
PAX5 repressed (Fuxa et al., 2004; Johnson et al., 
2004; Zhang et al., 2006; Cobaleda et al., 2007; 
Medvedovic et al., 2011). 
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PAX5/PML fusion protein. 
 
PML 
Location 
15q24.1 
Protein 
882 amino-acids (aa) and shorter isoforms with 
distinct C terminus sequences; from N-term to C-
term, PML contains: a proline rich domain (aa 3-
46); a zinc finger (RING finger type) (aa 57-92); 
two zinc fingers (B-box types) (aa 124-166 and aa 
183-236); a coiled coil made of hydrophobic aa 
heptad repeats (aa 228-253); an interaction domain 
with PER2 (aa 448-555); a nuclear localization 
signal (aa 476-490); a proline rich domain (aa 504-
583); a serine rich domain (aa 506-540); and a 
sumo interaction motif (aa 556-562).  
The RING finger, B-boxes, and coiled-coil region 
form a tripartite motif known as the TRIM or the 
RBCC motif, and is associated with E3 ubiquitin 
ligase activity.  
PML is the organizer of nuclear domains called 
nuclear bodies, which recruit a wide variety of 
proteins, most often sumoylated. PML is involved 
in DNA damage response, cell division control, 
chromosome instability, and is a clock regulator via 
regulation of PER2 expression. PML has pro-
apoptotic functions, induces senescence, inhibits 
angiogenesis and cell migration (Grignani et al., 
1996; Chen et al., 2012; de Thé et al., 2012). 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
Fusion of PAX5 exon 6 to PML exon 2. 
Fusion protein 
Description 
1099 amino acids. The predicted fusion protein 
contains the DNA binding paired domain of PAX5 
(260 aa from PAX5) and most of PML (839 aa). 
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